Securities
Issues & Trends
[Market In] Homeplus Receives 200 Billion Won in Funding… What Is the Timeline for Resuming Restructuring?
Homeplus, which has drawn up a plan to raise 200 billion won in emergency operating funds (DIP), is filing an immediate appeal with the court. Although the company has barely managed to keep its restr…
Issues & Trends
Shaperon Inc. Forms Partnership with U.S. Antibody Discovery Platform Company Leveragen
Shaperon Inc.(378800)is partnering with a global antibody discovery company to accelerate the development and commercialization of nanobody-based new drugs. Shaperon Inc. announced on the 20th that it…
Issues & Trends
KOSPI Plummets as Fear Overwhelms Earnings… “Rebound Expected in the Low to Mid-7,000 Range” (Roundup)
Analysts have concluded that the domestic stock market has been excessively depressed relative to corporate earnings fundamentals due to a confluence of negative factors, including the semiconductor i…
Issues & Trends
JETEMA Co.,Ltd. Unveils 'Total Bio Healthcare' Vision… "To Foster GLP-1 and Dermacosmetics"
Medical aesthetics and biopharmaceutical company JETEMA Co.,Ltd.(216080)has announced its vision to become a “global total bio-healthcare company” and plans to cultivate GLP-1-based obesity treatments…
Issues & Trends
LaonPeople Inc. Begins Full-Scale Growth as It Expands Its Generative AI and Golf Sensor Businesses
LaonPeople Inc.(300120)announced on the 20th that expectations for its medium- to long-term growth are rising as its generative AI (artificial intelligence) supply business and global golf operations …
Issues & Trends
Semiconductor Earnings Alone Are Not Enough… ‘Three Signs’ from Big Tech to Calm KOSPI Jitters
Analysts have suggested that the sharp decline in semiconductor stocks—despite strong earnings reports from major companies such as SamsungElectronics and TSMC—is due to the market’s focus shifting fr…
Issues & Trends
SAM CHUN DANG PHARM CO. LTD Officially Confirms FDA’s ‘Generic (ANDA) Development Pathway’
SAM CHUN DANG PHARM CO. LTD ( SAM CHUN DANG PHARM CO. LTD(000250)) announced on the 20th that it has received a response from the U.S. Food and Drug Administration (FDA) regarding its Pre-ANDA (Produc…
Issues & Trends
“Semiconductor Rebound Depends on Big Tech Earnings… Maintaining Capital Expenditures Is Key”
Although global semiconductor stocks fell sharply across the board, analysts have concluded that the recent correction appears excessive relative to corporate earnings conditions, given DRAM prices an…
Issues & Trends
“Extreme Volatility in the KOSPI Doesn’t Mean the Bull Market Is Over… The Answer Lies in Earnings Visibility”
Although the domestic stock market has recently been experiencing sharp fluctuations without any clear negative catalysts, analysts say it is too early to conclude that the bull market has ended. Whil…
Issues & Trends
“KOSPI Plummets, but the Semiconductor Cycle Isn’t Over… Orders from Big Tech Hold the Key to a Rebound”
Analysts have suggested that the recent sharp decline in the KOSPI is not so much due to the semiconductor industry having peaked and entered a downturn, but rather a price correction resulting from t…